8YY — Biolidics Cashflow Statement
0.000.00%
Last trade - 00:00- SG$31.10m
- SG$32.56m
- SG$0.78m
Annual cashflow statement for Biolidics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.68 | -6.04 | -9.85 | -2.49 | -3.19 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.2 | 0.697 | 5.53 | 0.315 | 0.718 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.939 | -0.531 | 0.07 | -0.034 | 0.036 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.43 | -4.62 | -3.06 | -1.97 | -2.31 |
| Capital Expenditures | -0.449 | -0.562 | -0.093 | 0 | -0.006 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.09 | -0.299 | 0.098 | -2.69 | 0.001 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.539 | -0.861 | 0.005 | -2.69 | -0.005 |
| Financing Cash Flow Items | -0.028 | 0 | -0.223 | -0.058 | -0.072 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.5 | -1.16 | 4.18 | -0.2 | 2.36 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.64 | -6.71 | 1.07 | -4.85 | 0.112 |